Official Title
Retrospective Study of Myocardial Damage in COVID-19
Brief Summary

This study aims to investigate the clinical characteristics, the incidence of myocardial injury, and the influence of myocardial injury on the prognosis in COVID-19 patients. There is no additional examination and treatment for this project.

Detailed Description

The epidemic of the COVID-19 has expanded from Wuhan through out China, and is being exported to a growing number of countries. Recently, investigators have revealed that acute myocardial injury is existed in 7.2% patients with COVID-19, and this proportion in patients admitted to the ICU (22.2%) is higher than patients not treated in the ICU (2.0%). Thus, cardiac troponin I (cTNI), the biomarker of cardiac injury, might be a clinical predictor of COVID-19 patient outcomes. This study aims to investigate the clinical characteristics, the incidence of myocardial injury, and the influence of myocardial injury on the prognosis in COVID-19 patients.

Enrolling by invitation
COVID-19
Cardiovascular Diseases

Other: non
no intervention
Dead group
Discharged group

Eligibility Criteria

Inclusion Criteria:

- (1) Age ≥18 years. (2) Laboratory (RT-PCR) confirmed infection with SARS-CoV-2. (3) Lung involvement confirmed with chest imaging.

Exclusion Criteria:

- No cTnI test on admission

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Countries
China
Wuhan Union Hospital, China
NCT Number
Keywords
Covid-19
myocardial injury
MeSH Terms
Cardiovascular Diseases